(1-甲基-1H-咪唑-4-基)甲胺 | 486414-83-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-甲基-1H-咪唑-4-基)甲胺
• 中文别名: (1-甲基-1氢-咪唑-4-基)甲胺
• 英文名称: (1-methyl-1H-imidazol-4-yl)methanamine
• 英文别名: (1-methyl-1H-imidazol-4-yl)methylamine；(1-methylimidazol-4-yl)methanamine
• CAS: 486414-83-9
• 化学式: C₅H₉N₃
• 分子量: 111.147
• InChiKey: YSEAGFBRAQOCFM-UHFFFAOYSA-N

物化性质

• 沸点：
  104 °C
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S23,S26,S36/37/39,S45
• 危险类别码：
  R22,R34
• 危险品运输编号：
  UN 2735
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P264,P270,P271,P280,P303+P361+P353,P304+P340,P305+P351+P338,P310,P330,P331,P363,P403+P233,P501
• 危险性描述：
  H302,H314

SDS

Name:	(1-Methyl-1H-imidazol-4-yl)methylamine Material Safety Data Sheet
Synonym:	None Known
CAS:	486414-83-9

Section 1 - Chemical Product MSDS Name:(1-Methyl-1H-imidazol-4-yl)methylamine Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
486414-83-9	(1-Methyl-1H-imidazol-4-yl)methylamine	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 486414-83-9: Personal Protective Equipment Eyes: Wear chemical splash goggles and face shield.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: Colourless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 104 - 108 deg C @0.2mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H9N3
Molecular Weight: 111.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Acid chlorides, strong oxidizing agents, strong acids.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 486414-83-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(1-Methyl-1H-imidazol-4-yl)methylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 22 Harmful if swallowed.
R 34 Causes burns.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 486414-83-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 486414-83-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 486414-83-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (1-甲基-1H-咪唑-4-基)甲胺 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 0.75h， 生成 N-[[(2R)-1-[4-(butylamino)-6-[(1-methylimidazol-4-yl)methylamino]-1,3,5-triazin-2-yl]pyrrolidin-2-yl]methyl]-4-propylbenzenesulfonamide
  参考文献：
  名称：

  Discovery of Highly Potent and Selective Small Molecule ADAMTS-5 Inhibitors That Inhibit Human Cartilage Degradation via Encoded Library Technology (ELT)

  摘要：

  The metalloprotease ADAMTS-5 is considered a potential target for the treatment of osteoarthritis. To identify selective inhibitors of ADAMTS-5, we employed encoded library technology (ELT), which enables affinity selection of small molecule binders from complex mixtures by DNA tagging. Selection of ADAMTS-5 against a four-billion member ELT library led to a novel inhibitor scaffold not containing a classical zinc-binding functionality. One exemplar, (R)-N-((1-(4-(but-3-en-1-ylamino)-6-(((2-(thiophen-2-yl)thiazol-4-yl)methyl)amino)-1,3,5-triazin-2-yl)pyrrolidin-2-yl)methyl)-4-propylbenzenesulfonamide (8), inhibited ADAMTS-5 with IC50 = 30 nM, showing >50-fold selectivity against ADAMTS-4 and >1000-fold selectivity against ADAMTS-1, ADAMTS-13, MMP-13, and TACE. Extensive SAR studies showed that potency and physicochemical properties of the scaffold could be further improved. Furthermore, in a human osteoarthritis cartilage explant study, compounds 8 and 15f inhibited aggrecanase-mediated (374)ARGS neoepitope release from aggrecan and glycosaminoglycan in response to IL-1 beta/OSM stimulation. This study provides the first small molecule evidence for the critical role of ADAMTS-5 in human cartilage degradation.

  DOI：

  10.1021/jm300449x
• 作为产物：
  描述：

  1-methyl-1H-imidazole-4-carbonyl chloride 在 lithium aluminium tetrahydride 、 氨 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 64.0h， 生成 (1-甲基-1H-咪唑-4-基)甲胺
  参考文献：
  名称：

  [EN] HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
  [FR] DÉRIVÉS DE 2-OXOQUINAZOLINE SUBSTITUÉS PAR UN ALKYLÈNE HÉTÉROARYLE UTILISÉS EN TANT QU'INHIBITEURS DE LA MÉTHIONINE ADÉNOSYLTRANSFÉRASE 2A

  摘要：

  本文披露了某些异芳基烷基取代的2-氧基喹唑啉衍生物的化学式(I)：(I)，它们是甲硫氨酸腺苷转移酶2A（MAT2A）抑制剂。还披露了包括这些化合物的药物组合物和治疗通过抑制MAT2A可治疗的疾病的方法，例如癌症，包括特征为甲基硫腺苷磷酸化酶（MTAP）活性降低或缺失的癌症。

  公开号：

  WO2021252678A1
• 作为试剂：
  描述：

  1-甲基-6,7-二甲氧基-3,4-二氢异喹啉 在 3-吗啉丙磺酸 、 (1-甲基-1H-咪唑-4-基)甲胺 、 [η⁵η5-(biot-2-(2,3,4,5-tetramethylcyclopentadienyl)ethylamine)IrCl₂]₂ 、 sodium formate 作用下， 以 水 为溶剂， 反应 18.0h， 生成 6,7-二甲氧基-1-甲基-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  铱（iii）生物素化的Cp *复合物中的8-氨基-5,6,7,8-四氢喹啉作为人工亚胺还原酶†

  摘要：

  研究了与生物素部分锚定在Cp *环上的铱金属络合物配位的二胺配体I-IV。与在人工亚胺还原酶中使用生物素化配体的传统生物素-链霉亲和素技术相反，该策略可用于设想不同链霉亲和素（Sav）突变体的对映体歧视如何影响金属辅因子的手性环境。仅在（R）-CAMPY IV的情况下由主体蛋白决定的在金属中心和第二配位球环境下的手性以协同方式起作用，在S112M Sav催化剂/催化剂比例为1.0：2.5时产生了更好的对映选择性。在这些优化条件下，人工亚胺还原酶在6,7-二甲氧基-1-甲基-3,4-二氢异喹啉的不对称转移氢化反应中提供了良好的对映体过量（83％）。

  DOI：

  10.1039/c8nj04558e

文献信息

• IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines
  作者：George M. Buckley、Richard Fosbeary、Joanne L. Fraser、Lewis Gowers、Alicia P. Higueruelo、Lynwen A. James、Kerry Jenkins、Stephen R. Mack、Trevor Morgan、David M. Parry、William R. Pitt、Oliver Rausch、Marianna D. Richard、Verity Sabin

  DOI：10.1016/j.bmcl.2008.04.042

  日期：2008.6

  Following the identification of a potent IRAK inhibitor through routine project cross screening, a novel class of IRAK-4 inhibitor was established. The SAR of imidazo[1,2-a]pyridino-pyridines and benzimidazolo-pyridines was explored.

  通过常规的项目交叉筛选鉴定出有效的IRAK抑制剂后，建立了新型的IRAK-4抑制剂。探索了咪唑并[1,2-a]吡啶基吡啶和苯并咪唑并吡啶的SAR。
• [EN] INHIBITORS OF APOL1 AND METHODS OF USING SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEURS MÉTHODES D'UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021154997A1

  公开（公告）日：2021-08-05

  The disclosure provides at least one entity chosen from compounds of Formula (I) pharmaceutically acceptable salts thereof, solvates of any of the foregoing, and deuterated derivatives of any of the foregoing, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

  披露提供了至少一个从公式(I)化合物、药用可接受的盐、上述任何物质的溶剂化物以及上述任何物质的重氢衍生物中选择的实体，包括含有相同实体的组合物，以及使用相同的方法，包括用于治疗APOL1介导的肾脏疾病。
• [EN] INHIBITORS OF APOL1 AND USE OF THE SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEUR UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2021252859A1

  公开（公告）日：2021-12-16

  The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.

  本公开提供了至少一种化合物、重氢化衍生物或药用可接受的盐，选自公式(I)化合物、其重氢化衍生物以及任何前述物质的药用可接受的盐，包含同一的组成物，以及制造和使用同一的方法，包括用于治疗APOL1介导的肾脏疾病。
• [EN] 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS<br/>[FR] AMIDES D'ACIDE 4-(5-ISOXAZOLYL OU 5-PYRAZOLYL-1,2,4-OXADIAZOL-3-YL)-MANDÉLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE DE TYPE 1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011133734A1

  公开（公告）日：2011-10-27

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物或其立体异构体、盐或前药，其中：Q是，或者R1是苯基，其上取代基为零至3个；而R1、R2、R3、R4、R5和G在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• [EN] SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF<br/>[FR] ACTIVATEURS À PETITES MOLÉCULES DE NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE (NAMPT) ET LEURS UTILISATIONS
  申请人：SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST

  公开号：WO2018132372A1

  公开（公告）日：2018-07-19

  Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

  本文提供了尼古丁酰胺磷酸核糖转移酶（NAMPT）的小分子激活剂，包括这些化合物的组合物，以及使用这些化合物和组合物的方法。